1
|
Gupta G, Kaur J, Bhattacharya K, Chambers BJ, Gazzi A, Furesi G, Rauner M, Fuoco C, Orecchioni M, Delogu LG, Haag L, Stehr JE, Thomen A, Bordes R, Malmberg P, Seisenbaeva GA, Kessler VG, Persson M, Fadeel B. Exploiting Mass Spectrometry to Unlock the Mechanism of Nanoparticle-Induced Inflammasome Activation. ACS NANO 2023; 17:17451-17467. [PMID: 37643371 PMCID: PMC10510732 DOI: 10.1021/acsnano.3c05600] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/21/2023] [Accepted: 08/21/2023] [Indexed: 08/31/2023]
Abstract
Nanoparticles (NPs) elicit sterile inflammation, but the underlying signaling pathways are poorly understood. Here, we report that human monocytes are particularly vulnerable to amorphous silica NPs, as evidenced by single-cell-based analysis of peripheral blood mononuclear cells using cytometry by time-of-flight (CyToF), while silane modification of the NPs mitigated their toxicity. Using human THP-1 cells as a model, we observed cellular internalization of silica NPs by nanoscale secondary ion mass spectrometry (nanoSIMS) and this was confirmed by transmission electron microscopy. Lipid droplet accumulation was also noted in the exposed cells. Furthermore, time-of-flight secondary ion mass spectrometry (ToF-SIMS) revealed specific changes in plasma membrane lipids, including phosphatidylcholine (PC) in silica NP-exposed cells, and subsequent studies suggested that lysophosphatidylcholine (LPC) acts as a cell autonomous signal for inflammasome activation in the absence of priming with a microbial ligand. Moreover, we found that silica NPs elicited NLRP3 inflammasome activation in monocytes, whereas cell death transpired through a non-apoptotic, lipid peroxidation-dependent mechanism. Together, these data further our understanding of the mechanism of sterile inflammation.
Collapse
Affiliation(s)
- Govind Gupta
- Institute
of Environmental Medicine, Karolinska Institutet, 171 77 Stockholm, Sweden
| | - Jasreen Kaur
- Institute
of Environmental Medicine, Karolinska Institutet, 171 77 Stockholm, Sweden
| | - Kunal Bhattacharya
- Institute
of Environmental Medicine, Karolinska Institutet, 171 77 Stockholm, Sweden
| | | | - Arianna Gazzi
- Department
of Biomedical Sciences, University of Padua, Padua 35121, Italy
| | - Giulia Furesi
- Department
of Medicine III and Center for Healthy Aging, TU Dresden, 01307 Dresden, Germany
| | - Martina Rauner
- Department
of Medicine III and Center for Healthy Aging, TU Dresden, 01307 Dresden, Germany
| | - Claudia Fuoco
- Department
of Biology, University of Rome Tor Vergata, Rome 00173, Italy
| | - Marco Orecchioni
- Division
of Inflammation Biology, La Jolla Institute
for Immunology, La Jolla, California 92037, United States
| | - Lucia Gemma Delogu
- Department
of Biomedical Sciences, University of Padua, Padua 35121, Italy
| | - Lars Haag
- Department
of Laboratory Medicine, Karolinska Institutet, 141 52 Huddinge, Sweden
| | - Jan Eric Stehr
- Department
of Physics, Chemistry and Biology, Linköping
University, 581 83 Linköping, Sweden
| | - Aurélien Thomen
- Department
of Chemistry and Molecular Biology, University
of Gothenburg, 412 96 Göteborg, Sweden
| | - Romain Bordes
- Department
of Chemistry and Chemical Engineering, Chalmers
University of Technology, 412 96 Göteborg, Sweden
| | - Per Malmberg
- Department
of Chemistry and Chemical Engineering, Chalmers
University of Technology, 412 96 Göteborg, Sweden
| | - Gulaim A. Seisenbaeva
- Department
of Molecular Sciences, Swedish University
of Agricultural Sciences, 750 07 Uppsala, Sweden
| | - Vadim G. Kessler
- Department
of Molecular Sciences, Swedish University
of Agricultural Sciences, 750 07 Uppsala, Sweden
| | - Michael Persson
- Department
of Chemistry and Chemical Engineering, Chalmers
University of Technology, 412 96 Göteborg, Sweden
| | - Bengt Fadeel
- Institute
of Environmental Medicine, Karolinska Institutet, 171 77 Stockholm, Sweden
| |
Collapse
|
2
|
Uzhytchak M, Smolková B, Lunova M, Frtús A, Jirsa M, Dejneka A, Lunov O. Lysosomal nanotoxicity: Impact of nanomedicines on lysosomal function. Adv Drug Deliv Rev 2023; 197:114828. [PMID: 37075952 DOI: 10.1016/j.addr.2023.114828] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2021] [Revised: 03/28/2023] [Accepted: 04/12/2023] [Indexed: 04/21/2023]
Abstract
Although several nanomedicines got clinical approval over the past two decades, the clinical translation rate is relatively small so far. There are many post-surveillance withdrawals of nanomedicines caused by various safety issues. For successful clinical advancement of nanotechnology, it is of unmet need to realize cellular and molecular foundation of nanotoxicity. Current data suggest that lysosomal dysfunction caused by nanoparticles is emerging as the most common intracellular trigger of nanotoxicity. This review analyzes prospect mechanisms of lysosomal dysfunction-mediated toxicity induced by nanoparticles. We summarized and critically assessed adverse drug reactions of current clinically approved nanomedicines. Importantly, we show that physicochemical properties have great impact on nanoparticles interaction with cells, excretion route and kinetics, and subsequently on toxicity. We analyzed literature on adverse reactions of current nanomedicines and hypothesized that adverse reactions might be linked with lysosomal dysfunction caused by nanomedicines. Finally, from our analysis it becomes clear that it is unjustifiable to generalize safety and toxicity of nanoparticles, since different particles possess distinct toxicological properties. We propose that the biological mechanism of the disease progression and treatment should be central in the optimization of nanoparticle design.
Collapse
Affiliation(s)
- Mariia Uzhytchak
- Institute of Physics of the Czech Academy of Sciences, 18221 Prague, Czech Republic
| | - Barbora Smolková
- Institute of Physics of the Czech Academy of Sciences, 18221 Prague, Czech Republic
| | - Mariia Lunova
- Institute of Physics of the Czech Academy of Sciences, 18221 Prague, Czech Republic; Institute for Clinical & Experimental Medicine (IKEM), 14021 Prague, Czech Republic
| | - Adam Frtús
- Institute of Physics of the Czech Academy of Sciences, 18221 Prague, Czech Republic
| | - Milan Jirsa
- Institute for Clinical & Experimental Medicine (IKEM), 14021 Prague, Czech Republic
| | - Alexandr Dejneka
- Institute of Physics of the Czech Academy of Sciences, 18221 Prague, Czech Republic
| | - Oleg Lunov
- Institute of Physics of the Czech Academy of Sciences, 18221 Prague, Czech Republic.
| |
Collapse
|
3
|
Coutinho Almeida-da-Silva CL, Cabido LF, Chin WC, Wang G, Ojcius DM, Li C. Interactions between silica and titanium nanoparticles and oral and gastrointestinal epithelia: Consequences for inflammatory diseases and cancer. Heliyon 2023; 9:e14022. [PMID: 36938417 PMCID: PMC10020104 DOI: 10.1016/j.heliyon.2023.e14022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2022] [Revised: 02/09/2023] [Accepted: 02/20/2023] [Indexed: 03/21/2023] Open
Abstract
Engineered nanoparticles (NPs) composed of elements such as silica and titanium, smaller than 100 nm in diameter and their aggregates, are found in consumer products such as cosmetics, food, antimicrobials and drug delivery systems, and oral health products such as toothpaste and dental materials. They may also interact accidently with epithelial tissues in the intestines and oral cavity, where they can aggregate into larger particles and induce inflammation through pathways such as inflammasome activation. Persistent inflammation can lead to precancerous lesions. Both the particles and lesions are difficult to detect in biopsies, especially in clinical settings that screen large numbers of patients. As diagnosis of early stages of disease can be lifesaving, there is growing interest in better understanding interactions between NPs and epithelium and developing rapid imaging techniques that could detect foreign particles and markers of inflammation in epithelial tissues. NPs can be labelled with fluorescence or radioactive isotopes, but it is challenging to detect unlabeled NPs with conventional imaging techniques. Different current imaging techniques such as synchrotron radiation X-ray fluorescence spectroscopy are discussed here. Improvements in imaging techniques, coupled with the use of machine learning tools, are needed before diagnosis of particles in biopsies by automated imaging could move usefully into the clinic.
Collapse
Affiliation(s)
| | - Leticia Ferreira Cabido
- Department of Oral and Maxillofacial Surgery, University of the Pacific, San Francisco, CA, USA
| | - Wei-Chun Chin
- Department of Bioengineering, University of California, Merced, CA, USA
| | - Ge Wang
- Department of Biomedical Engineering, Biomedical Imaging Center, Center for Biotechnology and Interdisciplinary Studies, Rensselaer Polytechnic Institute, Troy, NY 12180, USA
| | - David M Ojcius
- Department of Biomedical Sciences, University of the Pacific, San Francisco, CA, USA
| | - Changqing Li
- Department of Bioengineering, University of California, Merced, CA, USA
| |
Collapse
|
4
|
Sun H, Wang J. Novel perspective for protein-drug interaction analysis: atomic force microscope. Analyst 2023; 148:454-474. [PMID: 36398684 DOI: 10.1039/d2an01591a] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
Proteins are major drug targets, and drug-target interaction identification and analysis are important factors for drug discovery. Atomic force microscopy (AFM) is a powerful tool making it possible to image proteins with nanometric resolution and probe intermolecular forces under physiological conditions. We review recent studies conducted in the field of target protein drug discovery using AFM-based analysis technology, including drug-driven changes in nanomechanical properties of protein morphology and interactions. Underlying mechanisms (including thermodynamic and kinetic parameters) of the drug-target interaction and drug-modulating protein-protein interaction (PPI) on the surfaces of models or living cells are discussed. Furthermore, challenges and the outlook for the field are likewise discussed. Overall, this insight into the mechanical properties of protein-drug interactions provides an unprecedented information framework for rational drug discovery in the pharmaceutical field.
Collapse
Affiliation(s)
- Heng Sun
- Key Laboratory of Biorheological Science and Technology, Ministry of Education, College of Bioengineering, Chongqing University, Chongqing, 400044, China.
| | - Jianhua Wang
- Key Laboratory of Biorheological Science and Technology, Ministry of Education, College of Bioengineering, Chongqing University, Chongqing, 400044, China.
| |
Collapse
|
5
|
Ma L, Han Z, Yin H, Tian J, Zhang J, Li N, Ding C, Zhang L. Characterization of Cathepsin B in Mediating Silica Nanoparticle-Induced Macrophage Pyroptosis via an NLRP3-Dependent Manner. J Inflamm Res 2022; 15:4537-4545. [PMID: 35966002 PMCID: PMC9374095 DOI: 10.2147/jir.s371536] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2022] [Accepted: 07/30/2022] [Indexed: 12/02/2022] Open
Abstract
Introduction Silica nanoparticles (SiNPs) are one of the most widely used inorganic nanomaterials, and exposure to SiNP has been demonstrated to induce pulmonary inflammation, primarily promoted by the NLRP3-mediated macrophage pyroptosis. However, mechanisms underlying the activation of NLRP3 signaling are complex, and whether cathepsin B (CTSB), an enzyme released by the ruptured lysosome, could trigger NLRP3 assembly is controversial. Methods To further characterize the role of CTSB in silica-induced pyroptosis, we conducted this study by establishing SiNP exposure models in vitro. The morphological features of SiNPs were exhibited by the SEM and TEM, and the effects of SiNPs’ internalization on macrophages were examined by the TEM and immunofluorescent staining. Moreover, Western blot was performed to detect the expression of proteins related to pyroptosis and CTSB after blocking the expression of NLRP3 and CTSB. Results We found that SiNPs internalization caused the rupture of macrophage membrane and promoted the aging of cells with increased intracellular vacuoles. Also, the expression of NLRP3, ASC, Caspase-1, GSDMD, Pro-IL-1β, IL-1β, and CTSB increased under the stimulation of SiNP, which could be suppressed by additional treatment with MCC950, an NLRP3-specific inhibitor. Besides, we found SiNP joint treatment with leupeptin, a CTSB inhibitor, could inhibit the expression of CTSB, but it had no effect on the expression of NLRP3, ASC, and Caspase-1, and the process of macrophage pyroptosis was also not affected. Conclusion SiNP exposure induces rupture of macrophages and the release of lysosomal CTSB, but CTSB fails to specifically act on the NLRP3 inflammasome to induce pyroptosis which is causally linked to lung inflammation and fibrosis.
Collapse
Affiliation(s)
- Lan Ma
- School of Public Health, Weifang Medical University, Weifang, 261053, People's Republic of China.,Clinical Medical Research Center for Women and Children Diseases, Maternal and Child Health Care Hospital of Shandong Province, Shandong University, Jinan, 250001, People's Republic of China
| | - Zhengpu Han
- School of Public Health, Weifang Medical University, Weifang, 261053, People's Republic of China.,Clinical Medical Research Center for Women and Children Diseases, Maternal and Child Health Care Hospital of Shandong Province, Shandong University, Jinan, 250001, People's Republic of China
| | - Haoyu Yin
- School of Public Health, Weifang Medical University, Weifang, 261053, People's Republic of China.,Clinical Medical Research Center for Women and Children Diseases, Maternal and Child Health Care Hospital of Shandong Province, Shandong University, Jinan, 250001, People's Republic of China
| | - Jiaqi Tian
- School of Public Health, Weifang Medical University, Weifang, 261053, People's Republic of China.,Clinical Medical Research Center for Women and Children Diseases, Maternal and Child Health Care Hospital of Shandong Province, Shandong University, Jinan, 250001, People's Republic of China
| | - Jing Zhang
- School of Public Health, North China University of Science and Technology, Tangshan, 063210, People's Republic of China
| | - Ning Li
- School of Public Health, North China University of Science and Technology, Tangshan, 063210, People's Republic of China
| | - Chunjie Ding
- School of Public Health, Xinxiang Medical University, Xinxiang, 453000, People's Republic of China
| | - Lin Zhang
- Clinical Medical Research Center for Women and Children Diseases, Maternal and Child Health Care Hospital of Shandong Province, Shandong University, Jinan, 250001, People's Republic of China
| |
Collapse
|
6
|
Domingues C, Santos A, Alvarez-Lorenzo C, Concheiro A, Jarak I, Veiga F, Barbosa I, Dourado M, Figueiras A. Where Is Nano Today and Where Is It Headed? A Review of Nanomedicine and the Dilemma of Nanotoxicology. ACS NANO 2022; 16:9994-10041. [PMID: 35729778 DOI: 10.1021/acsnano.2c00128] [Citation(s) in RCA: 60] [Impact Index Per Article: 30.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
Abstract
Worldwide nanotechnology development and application have fueled many scientific advances, but technophilic expectations and technophobic demands must be counterbalanced in parallel. Some of the burning issues today are the following: (1) Where is nano today? (2) How good are the communication and investment networks between academia/research and governments? (3) Is there any spotlight application for nanotechnology? Nanomedicine is a particular arm of nanotechnology within the healthcare landscape, focused on diagnosis, treatment, and monitoring of emerging (such as coronavirus disease 2019, COVID-19) and contemporary (including diabetes, cardiovascular diseases, neurodegenerative disorders, and cancer) diseases. However, it may only represent the bright side of the coin. In fact, in the recent past, the concept of nanotoxicology has emerged to address the dark shadows of nanomedicine. The nanomedicine field requires more nanotoxicological studies to identify undesirable effects and guarantee safety. Here, we provide an overall perspective on nanomedicine and nanotoxicology as central pieces of the giant puzzle of nanotechnology. First, the impact of nanotechnology on education and research is highlighted, followed by market trends and scientific output tendencies. In the next section, the nanomedicine and nanotoxicology dilemma is addressed through the interplay of in silico, in vitro, and in vivo models with the support of omics and microfluidic approaches. Lastly, a reflection on the regulatory issues and clinical trials is provided. Finally, some conclusions and future perspectives are proposed for a clearer and safer translation of nanomedicines from the bench to the bedside.
Collapse
Affiliation(s)
- Cátia Domingues
- Univ. Coimbra, Faculty of Pharmacy, Galenic and Pharmaceutical Technology Laboratory, 3000-548 Coimbra, Portugal
- LAQV-REQUIMTE, Galenic and Pharmaceutical Technology Laboratory, Faculty of Pharmacy, Univ. Coimbra, 3000-548 Coimbra, Portugal
- Univ. Coimbra, Institute for Clinical and Biomedical Research (iCBR) Area of Environment Genetics and Oncobiology (CIMAGO), Faculty of Medicine, 3000-548 Coimbra, Portugal
| | - Ana Santos
- Univ. Coimbra, Faculty of Pharmacy, Galenic and Pharmaceutical Technology Laboratory, 3000-548 Coimbra, Portugal
| | - Carmen Alvarez-Lorenzo
- Departamento de Farmacología, Farmacia y Tecnología Farmacéutica, I+D Farma (GI-1645), Facultad de Farmacia, iMATUS, and Health Research Institute of Santiago de Compostela (IDIS), Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain
| | - Angel Concheiro
- Departamento de Farmacología, Farmacia y Tecnología Farmacéutica, I+D Farma (GI-1645), Facultad de Farmacia, iMATUS, and Health Research Institute of Santiago de Compostela (IDIS), Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain
| | - Ivana Jarak
- Univ. Coimbra, Faculty of Pharmacy, Galenic and Pharmaceutical Technology Laboratory, 3000-548 Coimbra, Portugal
| | - Francisco Veiga
- Univ. Coimbra, Faculty of Pharmacy, Galenic and Pharmaceutical Technology Laboratory, 3000-548 Coimbra, Portugal
- LAQV-REQUIMTE, Galenic and Pharmaceutical Technology Laboratory, Faculty of Pharmacy, Univ. Coimbra, 3000-548 Coimbra, Portugal
| | - Isabel Barbosa
- Univ. Coimbra, Faculty of Pharmacy, Phamaceutical Chemistry Laboratory, 3000-548 Coimbra, Portugal
| | - Marília Dourado
- Univ. Coimbra, Institute for Clinical and Biomedical Research (iCBR) Area of Environment Genetics and Oncobiology (CIMAGO), Faculty of Medicine, 3000-548 Coimbra, Portugal
- Univ. Coimbra, Center for Health Studies and Research of the University of Coimbra (CEISUC), Faculty of Medicine, 3000-548 Coimbra, Portugal
- Univ. Coimbra, Center for Studies and Development of Continuous and Palliative Care (CEDCCP), Faculty of Medicine, 3000-548 Coimbra, Portugal
| | - Ana Figueiras
- Univ. Coimbra, Faculty of Pharmacy, Galenic and Pharmaceutical Technology Laboratory, 3000-548 Coimbra, Portugal
- LAQV-REQUIMTE, Galenic and Pharmaceutical Technology Laboratory, Faculty of Pharmacy, Univ. Coimbra, 3000-548 Coimbra, Portugal
| |
Collapse
|